2021
Clinical Characteristics and Outcomes Associated With Oral Anticoagulant Use Among Patients Hospitalized With Intracerebral Hemorrhage
Xian Y, Zhang S, Inohara T, Grau-Sepulveda M, Matsouaka RA, Peterson ED, Piccini JP, Smith EE, Sheth KN, Bhatt DL, Fonarow GC, Schwamm LH. Clinical Characteristics and Outcomes Associated With Oral Anticoagulant Use Among Patients Hospitalized With Intracerebral Hemorrhage. JAMA Network Open 2021, 4: e2037438. PMID: 33591368, PMCID: PMC7887660, DOI: 10.1001/jamanetworkopen.2020.37438.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnticoagulantsCase-Control StudiesCerebral HemorrhageCohort StudiesDependent AmbulationDrug Therapy, CombinationDual Anti-Platelet TherapyFactor Xa InhibitorsFemaleFunctional StatusHospicesHospital MortalityHumansMaleMiddle AgedOdds RatioPatient DischargePlatelet Aggregation InhibitorsRegistriesRisk FactorsWarfarinConceptsOral anticoagulant useOral anticoagulantsFXa inhibitorsHospital mortalityAnticoagulant useCohort studyIndependent ambulationMRS scoreIntracerebral hemorrhageGuidelines-Stroke registryCardiovascular risk factorsHospital mortality riskFactor Xa inhibitorsConcomitant warfarinOral anticoagulationAnticoagulation therapyAntiplatelet therapyHospital outcomesClinical characteristicsRankin ScaleSecondary outcomesPrimary outcomeRisk factorsWorse outcomesHigh prevalence
2020
Evaluation of stroke incidence with duty‐cycled multielectrode‐phased radiofrequency ablation of persistent atrial fibrillation results of the VICTORY AF Study
Hummel J, Verma A, Calkins H, Schwamm L, Gress D, Wells D, Souza J, Hokanson R, Hemingway L, Stromberg K, Hoyt R, Wickliffe A, DeLurgio D, Boersma L. Evaluation of stroke incidence with duty‐cycled multielectrode‐phased radiofrequency ablation of persistent atrial fibrillation results of the VICTORY AF Study. Journal Of Cardiovascular Electrophysiology 2020, 31: 1289-1297. PMID: 32270538, DOI: 10.1111/jce.14483.Peer-Reviewed Original ResearchConceptsDevice-related strokesAcute procedural successAtrial fibrillationAF trialSecondary outcomesStroke incidenceProcedural successAF studyStroke/transient ischemic attackVitamin K antagonist anticoagulationMajor structural heart diseasePulmonary vein stenosisTransient ischemic attackIncidence of strokeStructural heart diseaseNumber of patientsVitamin K antagonismAtrial fibrillation resultsRigorous clinical evaluationIDE trialIschemic attackNeurologist assessmentPersAF patientsAF burdenPV stenosis
2018
Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality
Inohara T, Xian Y, Liang L, Matsouaka R, Saver J, Smith E, Schwamm L, Reeves M, Hernandez A, Bhatt D, Peterson E, Fonarow G. Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality. JAMA 2018, 319: 463-473. PMID: 29372247, PMCID: PMC5839299, DOI: 10.1001/jama.2017.21917.Peer-Reviewed Original ResearchConceptsHospital mortalityDual antiplatelet agentsIntracerebral hemorrhagePrior useOral anticoagulantsAntiplatelet agentsLower riskVitamin K Antagonist Oral AnticoagulantsK Antagonist Oral AnticoagulantsNon-vitamin K antagonistsGuidelines-Stroke hospitalsPrior antiplatelet therapyHospital mortality rateOral anticoagulant useRetrospective cohort studyWarfarin-treated patientsUse of OACInteraction p valuePrior strokeAnticoagulation therapyAntiplatelet therapyK antagonistsAnticoagulant useCohort studyHospital arrival
2017
Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation
Xian Y, O’Brien E, Liang L, Xu H, Schwamm L, Fonarow G, Bhatt D, Smith E, Olson D, Maisch L, Hannah D, Lindholm B, Lytle B, Pencina M, Hernandez A, Peterson E. Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. JAMA 2017, 317: 1057-1067. PMID: 28291892, DOI: 10.1001/jama.2017.1371.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeHistory of AFAntithrombotic therapyAntiplatelet therapyAntithrombotic treatmentAtrial fibrillationHospital mortalityTherapeutic warfarinTherapeutic anticoagulationSevere strokeIschemic strokeStroke severityLower oddsSubtherapeutic warfarinUnadjusted ratesAcute ischemic stroke severityGuidelines-Stroke programHealth Stroke ScaleIn-Hospital OutcomesHigh-risk patientsPrevalence of patientsRetrospective observational studyTime of strokeIschemic stroke severityHospital outcomesUse of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non–Vitamin K Antagonist Oral Anticoagulants Before Stroke
Xian Y, Federspiel J, Hernandez A, Laskowitz D, Schwamm L, Bhatt D, Smith E, Fonarow G, Peterson E. Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non–Vitamin K Antagonist Oral Anticoagulants Before Stroke. Circulation 2017, 135: 1024-1035. PMID: 28119380, DOI: 10.1161/circulationaha.116.023940.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravenousAgedAged, 80 and overAnticoagulantsDabigatranFemaleFibrinolytic AgentsHemorrhageHospital MortalityHumansInternational Normalized RatioMalePyrazolesPyridonesRecombinant ProteinsRegistriesRetrospective StudiesRisk FactorsRivaroxabanStrokeTime FactorsTissue Plasminogen ActivatorTreatment OutcomeWarfarinConceptsIntravenous rt-PASymptomatic intracranial hemorrhageIschemic strokeRt-PAIntracranial hemorrhageOdds ratioNon-Vitamin K Antagonist Oral AnticoagulantsIntravenous recombinant tissue plasminogen activatorK Antagonist Oral AnticoagulantsRecombinant tissue plasminogen activatorGuidelines-Stroke registrySerious systemic hemorrhageAcute ischemic strokeAdjusted odds ratioAmerican Heart AssociationTissue plasminogen activatorOutcomes of useHospital mortalityRegistry hospitalsOral anticoagulantsSevere strokeAdverse eventsProhibitive riskRankin ScaleThrombolytic therapy
2016
Acute management of stroke patients taking non–vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale
Xian Y, Hernandez A, Harding T, Fonarow G, Bhatt D, Suter R, Khan Y, Schwamm L, Peterson E. Acute management of stroke patients taking non–vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. American Heart Journal 2016, 182: 28-35. PMID: 27914497, DOI: 10.1016/j.ahj.2016.07.023.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAnticoagulantsAntithrombinsAtrial FibrillationCohort StudiesDabigatranEmergency TreatmentFemaleHumansMaleMedication Therapy ManagementOutcome and Process Assessment, Health CarePyrazolesPyridinesPyridonesQuality ImprovementRegistriesRivaroxabanStrokeThiazolesUnited StatesWarfarinConceptsAcute ischemic strokeAnticoagulation-related intracerebral hemorrhageIntracerebral hemorrhageIschemic strokeStroke patientsOral anticoagulantsAcute ischemic stroke patientsCurrent treatment patternsLongitudinal medication useMulticenter cohort studyAcute stroke patientsIschemic stroke patientsReal-world clinical decisionsChronic anticoagulation therapyPatient-reported outcomesCritical unmet needChronic anticoagulationGuidelines-StrokeStroke prophylaxisAnticoagulation therapyIndex hospitalizationStroke RegistryCohort studyAcute managementMedication use
2015
Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study
Xian Y, Wu J, O'Brien E, Fonarow G, Olson D, Schwamm L, Bhatt D, Smith E, Suter R, Hannah D, Lindholm B, Maisch L, Greiner M, Lytle B, Pencina M, Peterson E, Hernandez A. Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. The BMJ 2015, 351: h3786. PMID: 26232340, PMCID: PMC4521370, DOI: 10.1136/bmj.h3786.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsIschemic stroke patientsCoronary artery diseaseIschemic strokeWarfarin treatmentAtrial fibrillationArtery diseaseStroke patientsRisk of MACEImproved long-term clinical outcomesPrevious coronary artery diseaseLong-term clinical outcomesMore daysAdverse cardiovascular eventsHealth Stroke ScaleRecurrent ischemic strokeTerm clinical outcomesAtrial fibrillation patientsSurvivors of strokeLongitudinal outcomesReal-world effectivenessPatient prefersCardiovascular eventsOral anticoagulantsStroke ProgramNovel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack
Patel P, Zhao X, Fonarow G, Lytle B, Smith E, Xian Y, Bhatt D, Peterson E, Schwamm L, Hernandez A. Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. Circulation Cardiovascular Quality And Outcomes 2015, 8: 383-392. PMID: 26058721, PMCID: PMC4512906, DOI: 10.1161/circoutcomes.114.000907.Peer-Reviewed Original ResearchConceptsNovel oral anticoagulantsTransient ischemic attackAtrial fibrillation patientsIschemic attackIschemic strokeFibrillation patientsEligible patientsWarfarin therapyAtrial fibrillationNovel oral anticoagulant useCHA2DS2-VASc scoreRate of anticoagulationOral anticoagulant useLower stroke riskMultivariable logistic regressionAnticoagulation ratesGuidelines-StrokeNOAC useAnticoagulant useOral anticoagulantsStroke riskRisk factorsStudy populationPatterns of usePatients
2012
Risks of Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Receiving Warfarin and Treated With Intravenous Tissue Plasminogen Activator
Xian Y, Liang L, Smith E, Schwamm L, Reeves M, Olson D, Hernandez A, Fonarow G, Peterson E. Risks of Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Receiving Warfarin and Treated With Intravenous Tissue Plasminogen Activator. JAMA 2012, 307: 2600-2608. PMID: 22735429, DOI: 10.1001/jama.2012.6756.Peer-Reviewed Original ResearchConceptsIntravenous tissue plasminogen activatorInternational normalized ratioSymptomatic intracranial hemorrhageTissue plasminogen activatorSerious systemic hemorrhageIschemic strokeIntracranial hemorrhageSICH riskHospital mortalitySystemic hemorrhagePlasminogen activatorBaseline clinical factorsChronic warfarin therapyGuidelines-Stroke registrySecondary end pointsDegree of anticoagulationAmerican Heart AssociationRegistry hospitalsSICH rateSevere strokeWarfarin therapyClinical factorsComorbid conditionsHeart AssociationNormalized ratio
2008
Differential Use of Warfarin for Secondary Stroke Prevention in Patients With Various Types of Atrial Fibrillation
Lewis W, Fonarow G, LaBresh K, Cannon C, Pan W, Super D, Sorof S, Schwamm L. Differential Use of Warfarin for Secondary Stroke Prevention in Patients With Various Types of Atrial Fibrillation. The American Journal Of Cardiology 2008, 103: 227-231. PMID: 19121441, PMCID: PMC3086549, DOI: 10.1016/j.amjcard.2008.08.062.Peer-Reviewed Original ResearchConceptsECG-documented atrial fibrillationType of AFAtrial fibrillationQuality Improvement ProgramEligible patientsStroke preventionHistory of AFForm of AFSuch high-risk groupsSecondary stroke preventionTransient ischemic attackParoxysmal atrial fibrillationHigh-risk groupAnticoagulation guidelinesIschemic attackWarfarin useAnticoagulation therapyThromboembolic eventsElderly patientsHospital dischargeIschemic strokePresent admissionWarfarin therapyWarfarin treatmentMedical historyWarfarin Reversal in Anticoagulant-Associated Intracerebral Hemorrhage
Goldstein J, Rosand J, Schwamm L. Warfarin Reversal in Anticoagulant-Associated Intracerebral Hemorrhage. Neurocritical Care 2008, 9: 277-283. PMID: 18214714, DOI: 10.1007/s12028-008-9049-z.Peer-Reviewed Original ResearchConceptsFresh frozen plasmaIntravenous vitamin KProthrombin complex concentrateIntracerebral hemorrhageVitamin KWarfarin reversalClinical trialsCoagulation factorsCoagulation factor productsHalf of patientsMajority of survivorsDependent coagulation factorsHospital presentationDefinitive therapyTreatment optionsComplex concentrateAdjunct agentFrozen plasmaPermanent disabilityProcoagulant effectTreatment strategiesExpert guidelinesFactor VIIReal-world settingFactor products